Search Results

In Part One, we mapped out how laws and regulations interact, how the FDA is structured, and why blood is both a drug and a biologic. Now we turn to one of the most important dividing lines in cellular therapy regulation: the split between Section 351 and Section 361 of the Public Health Service (PHS) Act. This fork in the road determines how HCT/Ps (human cells, tissues, and cellular and tissue-based products) are regulated. Some are treated as 361 HCT/Ps  (tissues, regulated mainly for communicable disease control), while others are classified as 351 HCT/Ps  (biologics, requiring full FDA approval). It’s one of the first—and most consequential—questions to ask when thinking about any cellular product. The Four Criteria: 21 CFR 1271.10(a) FDA uses four criteria to decide if an HCT/P can remain a 361 product. To qualify, all four must be true : Minimal manipulation  — the tissue isn’t processed in a way that alters its original characteristics. Example : Cleaning, shaping, or cryopreserving a tendon = minimal. Digesting it into cells and reseeding a scaffold = more than minimal. Homologous use  — the product is used for the same function in the recipient as in the donor. Example : Cornea used to restore sight = homologous. Amniotic membrane marketed for “stem cell regenerative properties” = not homologous. Not combined with another active drug or device  — except for simple carriers or preservatives. No systemic effect / dependence on metabolic activity  — unless the use is autologous, in a first- or second-degree relative, or for reproductive use. This is the critical rule that separates many “tissues” from “biologics.” If a product fails even one of these, it is regulated as a 351 biologic. 361 HCT/P: The “Tissue” Path If all four criteria are met, the product stays under PHS Act 361  and 21 CFR 1271 (Subparts A–D) . Focus : communicable disease control, not clinical efficacy. Requirements : donor eligibility testing, good tissue practice (cGTP), registration and listing with FDA. Examples : tendons, corneas, skin grafts, bone fragments, semen. The Fourth Rule and Bone Marrow Transplants The “no systemic effect” rule is where confusion often arises. Most tissues—like tendons or corneas—are structural or local, so they qualify as 361. But what about hematopoietic stem cell (HSC) transplants ? Bone marrow, peripheral blood stem cells, and cord blood all have systemic effects  and depend on metabolic activity  to engraft and restore hematopoiesis. By the strict letter of the rule, they should be 351 biologics. FDA carves out an exception: if HSCs are for homologous use  (to reconstitute bone marrow), in an autologous setting , or between close relatives , they may remain under the 361 pathway. This is why routine bone marrow transplant programs operate under tissue-style regulation, not full BLAs. But once HSCs are expanded, manipulated, or gene-modified , they cross the line into 351. That’s why CAR-T cells  and ex vivo expanded HSCs  require more regulation. 351 HCT/P: The “Biologic” Path If you don’t meet all four criteria, you’re in PHS Act 351  territory. Regulation : under PHS 351, the FD&C Act, and Title 21 CFR (1271 + 210/211 + 600+). Burden : must demonstrate safety, purity, and potency to FDA’s satisfaction. Examples : CAR-T cells, most gene therapies, expanded stem cells. The Lifecycle of a 351 Product The development path is long, resource-intensive, and tightly monitored: Preclinical  — laboratory and animal studies show feasibility and basic safety. These are the foundation for first-in-human use. IND (Investigational New Drug application)  — filed with FDA before any patient receives the product. It includes preclinical data, detailed manufacturing protocols, and a proposed clinical trial plan. FDA reviews the IND mainly for patient safety . Clinical Trials Phase 1  → small numbers, focus on safety and dose-finding. Phase 2  → expands to measure efficacy signals while continuing safety monitoring. Phase 3  → large, often multicenter studies that provide definitive safety and efficacy data. BLA (Biologics License Application)  — the final submission. It must prove the product is safe, pure, and potent, and that the facility itself is GMP-compliant. FDA inspects the facility and reviews manufacturing controls as closely as it reviews clinical data. Post-market  — the responsibilities don’t stop at approval. Manufacturers must monitor for adverse events, report annually, and in some cases, conduct post-marketing studies. For CAR-T cells, each lot is tested and reviewed before release. This lifecycle explains why the cost and complexity of 351 products  is so much higher than 361. A tendon graft can move directly from a tissue bank to a surgeon. A CAR-T product must travel through a decade of trials and regulatory scrutiny before reaching a patient. Safety, Purity, and Potency: The Statutory Triad The PHS Act requires every biologic to be safe, pure, and potent.  For cellular products, those abstract words translate into specific assays: Safety Sterility testing (bacterial/fungal cultures) Mycoplasma PCR or culture Endotoxin (LAL assay) Replication-competent retrovirus (for gene-modified cells) Purity Flow cytometry (e.g., % CD3+ T cells in CAR-T products) Residual bead/cytokine/reagent testing Ensuring absence of contaminating cell types Potency Cytotoxicity assays (CAR-T killing tumor cells in vitro) Cytokine release assays (e.g., IFN-γ production) Colony-forming unit (CFU) assays for stem cells Differentiation assays for mesenchymal stromal cells These aren’t just lab tests—they’re the evidence that a product meets the PHS Act’s standard. They bridge the gap between statutory language and scientific reality. Why This Fork Matters The 351 vs. 361 split determines whether a product needs simple donor testing and tissue practice standards—or the full might of INDs, BLAs, and GMP inspections. It shapes the cost of therapies, the infrastructure required to deliver them, and the pace at which innovation reaches patients. Bone marrow, tendons, CAR-T cells—all fall somewhere on this spectrum. And the dividing line comes straight from the PHS Act, carried into practice through FDA’s regulations. 📌 Coming up in Part Three:  We’ll focus fully on the 361 world: tissues. What qualifies, what doesn’t, and how these products are regulated when they stay inside the 1271 box.

When I first dipped my toes into cellular therapy regulations, it felt like drowning in alphabet soup: PHS Act, FD&C Act, Title 21 CFR, CBER, CDER. Each acronym seemed to point in a different direction, and none of them came with a map. But beneath the jargon, there’s a simple framework: laws set the authority, regulations explain the rules, and FDA enforces both. Laws vs. Regulations: Who Does What? Laws  are written by Congress. They set the what : broad mandates about safety, efficacy, and public health. In our world, two laws matter most: The Public Health Service (PHS) Act  — governs biologics, including blood, tissues, and cellular therapies. It uses the famous triad: products must be safe, pure, and potent . The Federal Food, Drug, and Cosmetic (FD&C) Act  — governs drugs and devices, with a slightly different test: products must be safe and effective . Regulations  are written by FDA under the authority of those laws. They set the how . Regulations are published in the Code of Federal Regulations (CFR) , and for our field, it’s Title 21 (Food and Drugs) . 👉 Think of it this way: Congress says: “Biologics must be safe, pure, and potent.” FDA says: “Okay—here’s the rulebook for how you prove it: sterility testing, donor screening, validated potency assays, manufacturing standards.” The FDA’s Structure: Who Regulates What? FDA sits within the Department of Health and Human Services (HHS). Within FDA, there are centers —each with its own slice of responsibility. CBER (Center for Biologics Evaluation and Research)  → blood, cellular and gene therapies, tissues, vaccines, and related diagnostics. CDER (Center for Drug Evaluation and Research)  → drugs in the traditional sense: small molecules, monoclonal antibodies, most therapeutic proteins. That’s why CAR-T cell therapy  sits in CBER, while rituximab  (a monoclonal antibody) sits in CDER—even though both are used in hematology. This split confuses everyone at first, but it makes sense if you remember: CDER handles things that look like “chemicals in vials,” while CBER handles things that look like “cells, tissues, or blood.” Blood: The Perfect Example of Overlap Nothing illustrates the intersection of laws and regulations better than blood. Under the FD&C Act , blood is a drug . Under the PHS Act , blood is a biologic . That dual status means blood establishments must comply with a lattice of regulations : 21 CFR 210/211  — current good manufacturing practice (drugs). 21 CFR 600+  — general biologics requirements. 21 CFR 606  — blood establishment rules (donor eligibility, testing, quality systems). 21 CFR 640  — component-specific standards (RBCs, platelets, plasma, cryoprecipitate). If you’ve ever wondered why blood banking feels so heavily regulated, this is the reason: it’s both. Why Start Here? Because if you can understand how laws and regulations apply to blood—the most familiar cellular product—you’ll be better equipped to navigate the more complex world of stem cells, tissue grafts, and CAR-T therapies. Blood shows us three truths right away: Laws (PHS Act, FD&C Act) set the foundation. Regulations (21 CFR) provide the details. FDA (CBER/CDER) enforces both, often in overlapping ways. Once you see that pattern, the acronyms and numbers stop being noise. They start to form a map. 📌 Coming up in Part Two:  We’ll dig into the fork in the road between PHS 351 vs. 361 , how FDA decides if a product is a “biologic” versus a “tissue,” and what it actually takes for a 351 product to go from bench to bedside

Most of the time, our red cells are polite. They keep their surface antigens tucked away, only showing the parts of themselves that matter for ABO, Rh, and the usual cast of characters. But sometimes, hidden pieces of the red cell membrane — cryptantigens  — are suddenly exposed. When that happens, nearly every adult’s serum will react. The result is polyagglutination : the striking, messy agglutination of a patient’s red cells with most sera, even when ABO-compatible. It’s rare, it’s fascinating, and it can cause real confusion at the bench. Let’s walk through it. The Culprit: Cryptantigens Cryptantigens are usually masked by glycosylation or membrane structure. When they become exposed — through infection, clonal mutation, or inherited defects — they look like foreign antigens to the naturally occurring antibodies present in most adults. A key laboratory note: T family (T, Th, Tk, Tx)  antigens are recognized by Arachis hypogea (peanut) lectin . Tn antigen  is different — it is not recognized by peanut lectin , but is picked up by Helix pomatia (snail) lectin . Acquired Causes T Activation Mechanism:  Bacterial neuraminidase (from Clostridium perfringens , Streptococcus pneumoniae , and others) strips sialic acid from the red cell surface. Exposed antigens:  T, Th, Tk, Tx. Clinical associations:  Seen in sepsis, aHUS , and necrotizing enterocolitis . Key point:  This form is acquired and transient . Lab detection:  Arachis hypogea (peanut) lectin. Management:  Avoid plasma (full of anti-T antibodies), and if transfusion is necessary, use washed RBCs or platelets . Tn Polyagglutination Mechanism:  Acquired somatic mutation in a hematopoietic stem cell → defective glycosylation. Exposed antigen:  Tn antigen, distinct from the T family. Nature:   Acquired, clonal, persistent.  Sometimes shows mixed-field reactions. Lab detection:   Helix pomatia (snail) lectin , not peanut lectin. Associations:  May signal clonal hematopoiesis or preleukemic states. Inherited Causes HEMPAS (Congenital Dyserythropoietic Anemia II) Mechanism:  Inherited SEC23B mutation  → defective Golgi trafficking and incomplete glycosylation. Effect:  Cryptantigens are exposed and react with about one-third of adult sera . Clinical picture:  Chronic hemolytic anemia, multinucleated erythroblasts in marrow, positive acidified serum test. Hyde Park Polyagglutination Mechanism:  Inherited abnormal synthesis of Band 3  protein, described in individuals with Hemoglobin Hyde Park . Effect:  Membrane structural changes expose cryptantigens. Detection:  Confirmed with Sophora japonica lectin . Rarity:  Extremely uncommon, familial. Quick Reference Table Type Cause Exposed Antigen Nature Detection Notes T Activation Bacterial neuraminidase (infection) T, Th, Tk, Tx Acquired, transient Arachis hypogea (peanut) lectin Sepsis, aHUS, NEC; avoid plasma; wash RBCs/plt Tn Polyagglutination Somatic stem cell mutation Tn antigen Acquired, clonal Helix pomatia (snail) lectin Marrow disorders, preleukemia HEMPAS (CDA II) Inherited SEC23B  mutation Cryptantigens Inherited, persistent Acid serum test; ~1/3 sera positive Dyserythropoietic anemia Hyde Park Inherited abnormal Band 3 synthesis  (Hb Hyde Park) Cryptantigen Inherited, persistent Sophora japonica lectin Very rare familial condition Why It Matters Polyagglutination can be a diagnostic trap — suddenly, every crossmatch looks incompatible. Recognizing the pattern, reaching for lectins, and knowing which forms are acquired (T, Tn)  and which are inherited (HEMPAS, Hyde Park)  can help the blood banker avoid unnecessary delays, and in some cases, guide clinicians toward underlying conditions.

Most days in the blood bank, we’re juggling the usual suspects — ABO, Rh, Kell, Duffy, Kidd, MNS. But every now and then, an antibody pops up that doesn’t fit neatly into those boxes. That’s when the rare blood group systems come knocking: Diego, Cromer, Gerbich, and the rest of the “alphabet soup” that can send even seasoned transfusion medicine folks back to the reference books. These antigens don’t make headlines in every transfusion service, but when they do appear, they can mean the difference between finding compatible blood and delaying critical care. And the truth is — most of us don’t carry all these details in our heads. Why would we? They’re rare. But rare doesn’t mean unimportant. That’s why I put together a quick reference guide: something you can pull up on service, during board prep, or when you just need to remind yourself whether anti-Chido is clinically significant (spoiler: it’s not). What’s inside the guide Each system is broken down into: Antigens – high or low prevalence, defined where possible Genetics – the molecular basis (when known) Prevalence – who has it, and how often Antibody type – IgG vs IgM, reactivity patterns Clinical significance – HTRs, HDFN, or mostly nuisance Notes – testing pearls (like Sdᵃ being inhibited by guinea pig urine, or LWa being destroyed by DTT) I’ve included the systems that come up just enough to trip people up: Diego, Cromer, Gerbich, Chido/Rogers, Landsteiner–Wiener, Dombrock, Bennett–Goodspeed, Colton, Cartwright, Sid, and FORS. And for those who like to think ahead, there’s also a short overview of the 700 and 901 series (the collections and high-incidence buckets where tomorrow’s systems often begin). Why it matters For learners: Rare systems are high-yield board material, especially in transfusion medicine and immunohematology. For practice: Even if you never see anti-Wra in your blood bank career, you’ll eventually run into an antibody that doesn’t “fit” — and knowing how to interpret rarity vs significance is the key to safe transfusion. For curiosity: These systems are windows into red cell biology — from aquaporins to complement regulators to acetylcholinesterase. They remind us just how much the red cell carries beyond hemoglobin. Download the guide I’ve made the reference sheet available as a PDF download so you can keep it in your binder, your desktop, or your teaching slides: Final thought Blood group systems may be rare, but patients with rare antibodies are not imaginary. They show up in our hospitals, on our call nights, and in our transfusion reactions. Having a quick way to orient yourself can be the difference between feeling stuck and moving forward with confidence. This guide is my way of sharing a tool I wish I had earlier — compact, high-yield, and practical. I hope it helps you, your trainees, or your colleagues the next time an “uncommon and unforgettable” antibody shows up on your bench.

One of the challenges in transfusion medicine is that the most important areas of knowledge are not always the most glamorous. Beyond the intricacies of blood components, cellular therapies, and patient blood management, transfusion medicine professionals also need a solid foundation in statistics, quality systems, and regulatory frameworks. These topics often feel scattered — a little bit in textbooks, a little in regulatory documents, a little in accreditation checklists. They are also written in different languages: statistics speaks in sensitivity and specificity, regulations in acronyms and federal code, quality systems in cycles and root cause analyses. For learners, it can feel like stitching together three dialects just to follow one conversation. To help simplify this, I’ve created the Transfusion Medicine Quick Guides. These are concise, practical summaries designed to: Bring the key statistical concepts (sensitivity, specificity, PPV, NPV, likelihood ratios, Westgard rules, ROC curves, and how prevalence shapes predictive values) into one place. Clarify the major quality and regulatory frameworks, including the roles of CLIA, FDA, AABB, CAP, and FACT, as well as quality control vs quality assurance, process improvement tools, and hemovigilance. Provide a crosswalk of commonly confused terms, such as validation vs verification vs calibration, deviation vs deficiency, and error vs adverse event. These guides are written to be accessible whether you are: Preparing for transfusion medicine boards, Training residents, fellows, or laboratory staff, Or just refreshing your own memory before an inspection. 📄 Download the complete Transfusion Medicine Quick Guides (PDF) below: I hope this resource saves you time, provides clarity, and makes the less glamorous but deeply important side of transfusion medicine a little easier to navigate. 📌 Usage & Sharing This resource is free to use and share for educational purposes. Please credit Blood, Bytes, and Beyond  as the source if you distribute it or incorporate it into teaching materials.

When I first wrote my Fresh Frozen Facts  series, I focused on the workhorses. But plasma isn’t a single product: it’s a whole family, with cousins and spin-offs that have slightly different strengths, weaknesses, and roles. Today, let’s walk through the “plasma family tree” and see how FFP compares to PF24, thawed plasma, liquid plasma, cryopoor plasma, and solvent/detergent–treated plasma like Octaplas. 🧊 FFP (Fresh Frozen Plasma) Frozen within 8 hours of collection. Retains nearly all labile factors (especially V and VIII). Shelf life: 1 year at ≤ –18°C. Indications: the broad-spectrum plasma support we all know. ❌ Con: Requires freezer storage and thawing (30+ minutes), not “immediately available” in an emergency. ⏱️ PF24 (Plasma Frozen within 24 Hours) Frozen within 24 hours instead of 8. Reduced factor VIII, otherwise very similar to FFP. Shelf life: 1 year at ≤ –18°C. Often interchangeable with FFP in clinical practice. ❌ Con: That reduction in factor VIII may matter in certain bleeding disorders, though usually it is clinically insignificant. ❄️ Thawed Plasma FFP or PF24 that has been thawed and then stored at 1–6°C. Shelf life: up to 5 days after thawing. Factor V and VIII decline gradually, but most other factors remain stable. Role: stocked in some hospitals for faster turnaround in emergencies when FFP/PF24 would take too long to thaw. ❌ Con: Slightly reduced factor activity compared to freshly thawed FFP/PF24; short post-thaw shelf life. 💧 Liquid Plasma Collected and stored as plasma, never frozen. Stored at 1–6°C, shelf life up to 26–40 days (depending on regulatory body). Factor V and VIII decline during storage. Role: often stocked in trauma centers as “always ready” plasma for massive transfusion protocols (MTPs). ❌ Con: Lower levels of labile clotting factors make it less suitable for patients who need high VIII activity. 🩸 Cryopoor Plasma (CPP, Cryosupernatant) Plasma remaining after cryoprecipitate removal. Depleted in fibrinogen, factor VIII, and large vWF multimers. ADAMTS13 levels are normal, which is why CPP has been used as replacement fluid in TTP during therapeutic plasma exchange (TPE). Rarely used in the U.S. today, but still a recognized product. ❌ Con: Limited hemostatic utility outside TTP; largely obsolete for most other indications. 🧪 S/D Plasma (Solvent/Detergent–Treated Plasma) Plasma pooled from many donors, treated with solvent/detergent to inactivate lipid-enveloped viruses (HIV, HBV, HCV, etc.). Advantages: pathogen reduction, standardized factor levels, lower TRALI risk. Limitations: does not  inactivate non-enveloped viruses (HAV, parvovirus B19). Globally available under several names, but in the U.S. we use Octaplas. ❌ Con: Pooling introduces theoretical risk of donor-derived rare pathogens slipping through; supply and cost can also be limiting. 🌍 Octaplas (S/D Plasma, Octapharma) FDA-approved form of S/D plasma. Beyond solvent/detergent, Octaplas is passed through a PrP resin column to reduce abnormal prion proteins — a unique step not shared by all S/D plasmas worldwide. The clinical utility of this prion clearance step is unknown, but it is part of the FDA approval package. Indications: same as FFP, but often chosen for patients with multiple transfusion reactions or when pathogen-reduced products are preferred. Advantages: lower allergic reaction rates, consistency across units, potential added prion safety. ❌ Con: Expensive, availability may be limited compared to standard FFP/PF24, and not all institutions stock it. 🧾 Plasma Comparison Table Product Prep/Storage Factor Content Special Uses Pathogen/Prion Reduction Cons FFP Freeze ≤8h, –18°C, 1 yr Full (incl. labile factors) General plasma support Standard donor testing only Requires freezer/thaw time; not immediately available PF24 Freeze ≤24h, –18°C, 1 yr Slight ↓ VIII Interchangeable with FFP Standard donor testing only Slightly lower VIII levels Thawed Plasma Thawed FFP/PF24, 1–6°C, 5 d ↓ V, VIII over time Faster turnaround in emergencies Standard donor testing only Reduced factor activity; short post-thaw life Liquid Plasma Never frozen, 1–6°C, 26–40 d ↓ V, VIII over time “Always ready” for MTPs Standard donor testing only Declining clotting factor activity Cryopoor Plasma Post-cryoprecipitate Low fibrinogen, VIII, vWF multimers; normal ADAMTS13 TTP (replacement during TPE) Standard donor testing only Obsolete for most other uses S/D Plasma Pooled, solvent/detergent treated Standardized Broad use, ↓ TRALI risk Inactivates lipid-enveloped viruses only Doesn’t target non-enveloped viruses; cost Octaplas Pooled, solvent/detergent + PrP column Standardized Broad use, ↓ reactions Viral inactivation + PrP resin (prion clearance; clinical utility unknown) Higher cost; limited availability 🌟 Takeaway Plasma is not one-size-fits-all. FFP and PF24 dominate day-to-day use, but thawed plasma, liquid plasma, cryopoor plasma, and S/D products like Octaplas each have unique features and limitations. Knowing the differences — from “always ready” trauma plasma to prion-cleared Octaplas — helps match the right plasma to the right patient.

Mahesar A, et al. Platelet refractoriness during bone marrow transplantation: Comparison in aplastic anemia and beta thalassemia major patients. An experience of a public sector BMT unit in Pakistan. Biol Blood Marrow Transplant.  2020;26(3)(suppl):S210-S211. Introduction Platelet transfusion is a cornerstone of supportive care in hematology, oncology, and critical care. But what happens when patients fail to respond as expected? This phenomenon, known as platelet refractoriness , is defined as the failure to achieve the anticipated post-transfusion platelet count increment. Refractoriness matters because it is linked to an increased risk of bleeding, greater transfusion requirements, and significant challenges for both patient management and blood supply utilization. Measuring Refractoriness The most widely used tool for assessing platelet transfusion response is the Corrected Count Increment (CCI) . This metric adjusts the raw post-transfusion platelet count for patient size and the platelet dose received. CCI  = [(post-count – pre-count) × body surface area (m²)] ÷ number of platelets transfused (×10¹¹) Clinically, refractoriness is generally defined as a 1-hour CCI < 5,000–7,500 , though cutoffs may vary slightly between institutions. Causes of Platelet Refractoriness The causes of refractoriness fall broadly into non-immune  and immune  categories. Non-immune causes (most common): These account for the majority of cases and include fever, infection or sepsis, disseminated intravascular coagulation (DIC), splenomegaly, active bleeding, and certain medications. Because they are so common, they should always be considered first. Immune causes: When non-immune factors have been ruled out, immune mechanisms come into play. The most frequent is alloimmunization against human leukocyte antigens (HLA) . While the name suggests they only exist on leukocytes, HLA Class I antigens are also expressed on platelets. Less commonly, patients may develop antibodies against human platelet antigens (HPA) , typically seen in multiparous women or multiply transfused individuals. Evaluation A systematic evaluation helps distinguish between common, reversible factors and true alloimmune refractoriness. Step 1: Rule out non-immune contributors Review recent clinical events: fever, infection, sepsis, ongoing bleeding, or DIC. Assess splenomegaly via exam or imaging. Review medication list for drugs that impair platelet function or survival (e.g., amphotericin, vancomycin, certain antibiotics, heparin). Correct or stabilize these factors whenever possible. Many patients improve simply by addressing these issues. Step 2: Laboratory testing if refractoriness persists: If non-immune factors are unlikely or have been addressed, lab evaluation is the next step: HLA typing (donor and/or patient): Typing is typically performed at the DNA level (PCR-based molecular methods) to determine the patient’s HLA Class I antigens. This allows selection of compatible platelet donors. HLA antibody screen: Patient serum is tested against a panel of HLA antigens using solid-phase assays (e.g., bead-based methods on flow cytometry or Luminex platforms). This identifies alloantibodies and their specificities. Panel Reactive Antibody (PRA): PRA is a summary measure that estimates the percentage of the donor population against which the patient has HLA antibodies. A higher PRA indicates broader sensitization and fewer compatible donors. Platelet crossmatch: Patient serum is incubated with donor platelets to detect compatibility. This is usually performed by flow cytometry or solid-phase assays. Crossmatching has the advantage of providing a result within hours and can capture both HLA and HPA incompatibilities. HPA testing: In select cases where HPA alloimmunization is suspected (often multiparous women or heavily transfused patients), molecular typing of the patient and donor, along with antibody testing, can identify incompatibilities. HPA testing is less common but may explain rare refractory cases. This structured workflow ensures that patients are not prematurely labeled as “immune refractory,” avoiding unnecessary use of scarce matched products. Management Treatment depends on the underlying cause: Non-immune causes:  Addressing the underlying condition is paramount—controlling infection, managing DIC, stopping an offending drug, or stabilizing bleeding. Optimizing the patient’s overall clinical status often restores transfusion responsiveness. Immune causes: HLA-compatible platelets:  The most common first step. This involves selecting donor platelets that lack the specific HLA antigens against which the patient has antibodies. Often identified using antibody specificity prediction or virtual crossmatching. HLA-matched platelets:  Platelets selected from donors who share the patient’s HLA type. Sourcing typically relies on registry databases or directed donation. Crossmatched platelets:  A faster and more practical option than full HLA-matching, particularly useful when PRA is low or turnaround time is critical. Again, crossmatching will identify incompatibility with both HLA and HPA antigens. PRA-guided strategy:  A PRA ≥ 20%  indicates a significant alloimmunization burden, meaning random donor platelets are unlikely to be compatible. At this threshold, the additional expense and labor of selecting matched or compatible platelets is justified. HPA-matched platelets:  Reserved for rare, complex cases when HPA antibodies are confirmed. Adjunctive measures:  Antifibrinolytics and other supportive therapies may be used in bleeding patients while definitive therapy is arranged. Practical Challenges Even with the best plan, management is rarely straightforward. Donor availability is limited, testing and procurement take time, and resource constraints often force compromises between the ideal and the feasible. Clinicians must balance patient safety, transfusion stewardship, and logistical realities. Conclusion Platelet refractoriness is a complex and often multifactorial problem . The majority of cases are non-immune in origin, but immune causes—particularly HLA alloimmunization—pose significant challenges. A systematic approach that prioritizes ruling out common non-immune contributors, followed by targeted immune evaluation and thoughtful transfusion strategy, helps ensure that patients receive the safest and most effective care possible.

I’ve been taught a lot about resilience. It’s a buzzword now — built into wellness curricula, baked into institutional language, handed out like a balm for burnout. We’re offered resiliency toolkits and mindfulness apps, taught breathing exercises and positive reframing. The idea is that if we just regulate our emotions well enough, we can withstand anything. In theory, it’s empowering. In practice, it often feels hollow. Because real resilience — the kind forged in complex, unjust, high-pressure environments — looks nothing like a slide deck. It isn’t always calm. It isn’t always pretty. And it certainly isn’t a personal growth opportunity neatly disguised as institutional neglect. What no one tells you is that resilience sometimes looks like grief. Or anger. Or stubborn silence. It looks like being misunderstood and still showing up. It looks like refusing to disappear — even when invisibility would be safer. Resilience isn’t about bouncing back. It’s about remaining yourself when everything around you suggests you shouldn’t. The Tension in Mastering Our Fates Invictus By William Ernest Henley   Out of the night that covers me, Black as the Pit from pole to pole, I thank whatever gods may be For my unconquerable soul. In the fell clutch of circumstance I have not winced nor cried aloud. Under the bludgeonings of chance My head is bloody, but unbowed. Beyond this place of wrath and tears Looms but the Horror of the shade, And yet the menace of the years Finds, and shall find me, unafraid. It matters not how strait the gate, How charged with punishments the scroll, I am the master of my fate, I am the captain of my soul. Henley’s words are spare and defiant, clenched against the world. They speak of a soul that cannot be conquered, no matter the pain or the pressure. And yet, as much as I love this poem — and I do — I’ve also come to see its limits. Because we are not  the masters of our fate, not entirely. The scroll is charged with punishments we didn’t write. The gate is narrow for reasons we didn’t choose. Control is unevenly distributed, privilege unevenly granted. And still, Henley’s voice offers something that is true: when all else is taken, we still have ourselves. Our will. Our response. Our refusal to bow. Amanda Knox and the Interior Life That truth echoes in an essay by Amanda Knox, reflecting on her years in an Italian prison for a crime she did not commit. She describes the moment when she realized, fully and finally: This is still my life. Not the life she wanted, not the one she planned, but hers nonetheless. And within that stark, narrow space, she still had choices — how to spend her time, how to carry herself, how to stay human in a place designed to strip that away. That moment has stayed with me. Because her insight wasn’t grand or defiant — it was intimate. She didn’t rise with poetry. She simply claimed her own interior  in a place that sought to erase it. It made me realize that resilience isn’t always loud. It isn’t always visible. Sometimes it looks like survival inside a system designed to break you. Sometimes it’s choosing to live  in a life you didn’t ask for, with dignity, depth, and deliberate care. Maya Angelou and the Radiance of Refusal Still I Rise By Maya Angelou   You may write me down in history With your bitter, twisted lies, You may trod me in the very dirt But still, like dust, I'll rise.   Does my sassiness upset you? Why are you beset with gloom? ’Cause I walk like I've got oil wells Pumping in my living room.   Just like moons and like suns, With the certainty of tides, Just like hopes springing high, Still I'll rise.   Did you want to see me broken? Bowed head and lowered eyes? Shoulders falling down like teardrops, Weakened by my soulful cries?   Does my haughtiness offend you? Don't you take it awful hard ’Cause I laugh like I've got gold mines Diggin’ in my own backyard.   You may shoot me with your words, You may cut me with your eyes, You may kill me with your hatefulness, But still, like air, I’ll rise.   Does my sexiness upset you? Does it come as a surprise That I dance like I've got diamonds At the meeting of my thighs?   Out of the huts of history’s shame I rise Up from a past that’s rooted in pain I rise I'm a black ocean, leaping and wide, Welling and swelling I bear in the tide.   Leaving behind nights of terror and fear I rise Into a daybreak that’s wondrously clear I rise Bringing the gifts that my ancestors gave, I am the dream and the hope of the slave. I rise I rise I rise.   Where Henley grits his teeth and Knox reclaims her interior, Maya Angelou rises. Not just surviving — but refusing to be erased. Her resilience isn’t armored or stoic; it’s radiant, embodied, and unmistakably hers. She doesn’t shrink, doesn’t explain, doesn’t wait to be welcomed. She rises — again and again — like something inevitable. But rising like that doesn’t happen by accident. It takes effort to move with grace through a world that wants you flattened. It takes energy to meet erasure with joy — or even with composure. Angelou’s poem isn’t just a declaration. It’s a record of resistance, of showing up with presence and power when everything pushes you to vanish. And that’s what resiliency training never touches: Not just the courage it takes to keep going, but the labor of continuing. The Work of Resilience Resilience, as it’s often presented, sounds passive — like a quality you either possess or don’t. But the real thing takes labor. It takes waking up after another night of unrest and doing what needs to be done anyway. It takes managing perception, emotion, logistics, and reputation — often simultaneously. It takes discerning what to fight for and what to let go. It takes choosing, again and again, not to go numb. And even that’s not always enough. Because no one is resilient alone . There are privileges that make resilience possible: safety nets, mentors, second chances, being believed. There’s chance and timing and luck. There are people who see you when you’re breaking and quietly help hold the pieces together. Without those, survival can feel like a private, grinding miracle — the kind that looks effortless from the outside but costs everything on the inside. That’s what no one tells you. Resilience isn’t a glow-up. It’s a grind. And for most of those who live it, there’s no award, no parade — just the quiet, difficult work of continuing. What’s Left Out of the Slide Deck Resilience isn’t a personal virtue. It’s a practice. A labor. A negotiation between who you are and what the world demands of you. It’s not about bouncing back — it’s about carrying on in a life you didn’t ask for, in systems that weren't designed for you, with people who may never understand what it costs you to be there. Sometimes resilience looks like grace. Sometimes it looks like exhaustion. Sometimes it looks like a person who keeps showing up — not because it’s redemptive, but because it’s necessary. That’s the part we leave out: Not that resilience is rare, but that it is hard. And it’s still happening, quietly, in people all around you — whether you recognize it or not.

This week, I graduate from my transfusion medicine fellowship at the NIH. It’s the culmination of a year that was equal parts challenging and productive — a year in which I learned not just by observing, but by building. And now that I’m closing this chapter, I want to take a moment to reflect on what I built. 🛠 Process and Quality Improvement From day one, I gravitated toward problems I could fix. I helped rewrite the Blood Services Section guide for fellows, corrected longstanding issues in key computation tools, and developed new order sets to streamline workflows and reduce risk. I also authored a standardized transfusion reaction holy book with impressions and recommendations for over 12 different transfusion reactions, including literature citations, and I also created a standardized note template to support more consistent documentation across the team. And I made major updates to the platelet script — a vital tool used to guide transfusion medicine physicians through complex platelet ordering decisions. 📄 Publications My research on total blood volume estimation in obesity yielded two first-author publications. I also first-authored a case report (in press) and published a formal response to a letter to the editor — sharpening both my scientific voice and my advocacy for evidence-based transfusion. 🎓 Professional Development Along the way, I completed the AABB Cell Therapies Certificate Program, earned QIA certification, and participated in ASCP's leadership institute. I also worked through the entire Transfusion Medicine Self-Assessment and Review  to prepare for boards — a reminder that learning doesn’t stop between projects or during service. 🩸 Writing and Outreach I shared my perspectives through essays in Critical Values  and The Pathologist , tackling complex and sometimes uncomfortable issues in laboratory medicine. And I kept writing here — publishing multi-part blog series on platelet products and fresh frozen plasma (FFP), with the goal of making nuanced transfusion topics a little more accessible to busy clinicians and curious trainees alike. 🧑‍🏫 Education I delivered formal lectures on pediatric transfusion, obstetrical transfusion, and hematopoietic progenitor cell (HPC) mobilization — each one tailored to the specific challenges of learners and the clinical context in which they were practicing. 🤝 Supporting the Team I covered service and call for colleagues when needed and made a point of writing commendations (“High Quality Service STARs”) to recognize the work of others. Because part of building something good — especially in medicine — is noticing what others are building, too. Graduating from fellowship isn’t just about checking boxes. For me, it’s about knowing I left something better than I found it. That I contributed to the field in a meaningful way. And that I’m heading into the next phase of my career not just trained, but ready. Next stop: Assistant Professor of Pathology at the University of Wisconsin. Onward.

We’ve spent the last three posts talking about plasma as a transfusion product — thawed, typed, delivered in a blood bag, and used (too often) without a clear plan. But plasma isn’t just a transfusion product. It’s also the raw material for a whole class of plasma-derived pharmaceuticals — therapies that are purified, concentrated, and engineered for targeted clinical use. These aren’t “just” blood products. They’re manufactured biologics, held to rigorous standards, and often used with precision in hematology, neurology, rheumatology, immunology, and beyond. Let’s look at some of the most important players — and how they work. Albumin: The Volume Expander That Isn’t Just Volume Derived from pooled human plasma and purified to 5% or 25% concentrations. Maintains oncotic pressure, draws fluid into the intravascular space. Used in volume-sensitive resuscitation (e.g., cirrhosis with tense ascites, nephrotic syndrome, plasmapheresis), but not for general volume expansion. Doesn’t correct coagulopathy or replace clotting factors. Also used as a replacement fluid in some apheresis protocols. Pearl: If you’re reaching for FFP "for volume," ask yourself: is albumin the right choice instead? IVIG: Immune Modulator with Broad Utility Intravenous immunoglobulin (IVIG) is made from pooled plasma from thousands of donors. Contains primarily IgG, with small amounts of other immunoglobulin classes. Used to neutralize autoantibodies, modulate immune response, or replenish IgG in patients with antibody deficiencies. Common indications: ITP, autoimmune hemolytic anemia Guillain-Barré syndrome, myasthenia gravis, CIDP Primary immunodeficiencies Kawasaki disease Risks: Headache, thromboembolic events, aseptic meningitis, renal dysfunction (especially with sucrose-containing products). Pearl: IVIG is expensive, powerful, and slow to infuse — use with intention, not desperation. Rh Immune Globulin (RhIg/RhoGAM): Small Dose, Big Impact Concentrated anti-D antibodies made from Rh-negative donors sensitized to D antigen. Administered to Rh-negative patients exposed to Rh-positive RBCs — most commonly pregnant patients or following transfusion errors. Primary use: Preventing alloimmunization in Rh-negative pregnant individuals carrying Rh-positive fetuses. Also used in ITP as an alternative to IVIG (particularly in children), though less commonly now. Mechanism in ITP: Coats D-positive RBCs, redirecting macrophage clearance and sparing platelets. Pearl: One of the oldest, most elegant forms of targeted immune modulation — and a triumph of transfusion medicine. Other Plasma-Derived Therapies Anti-Tetanus, Anti-Rabies, and Other Hyperimmune Globulins Pooled antibodies from vaccinated donors. Used for post-exposure prophylaxis or treatment of rare infections. Includes hepatitis B immune globulin (HBIG), cytomegalovirus immune globulin (CMV-IG), and more. Antithrombin Concentrate Used in hereditary antithrombin deficiency, especially during pregnancy or surgery. Also considered in select ECMO or cardiac surgery patients with heparin resistance. C1 Esterase Inhibitor For hereditary angioedema (HAE), where C1-INH deficiency leads to bradykinin-mediated swelling. Plasma-derived and recombinant versions exist. Factor Concentrates Covered in Part III, but worth reiterating: purified concentrates for hemophilia A/B, factor XIII deficiency, von Willebrand disease, and more. Far more effective than FFP when a specific deficiency is known. Patient-Centered Considerations Plasma-derived therapies aren’t just pharmacologic tools — they’re also part of the complex, personal decision-making that happens between patients and providers. For example, some Jehovah’s Witnesses — who decline transfusion of whole blood, red cells, platelets, or plasma — may accept plasma-derived fractions such as albumin, IVIG, or clotting factor concentrates. Whether these are acceptable is a deeply individual decision, often informed by religious interpretation and personal conviction. Respecting these boundaries, and knowing what options exist beyond standard transfusion, is essential to providing care that aligns with a patient’s values. It’s also worth remembering the complicated history of clotting factor concentrates. In the 1980s and ’90s, many recipients — particularly people with hemophilia — were devastated by transfusion-transmitted infections like HIV and hepatitis C, sometimes acquired through pooled plasma products. For decades afterward, even their sexual partners were deferred from blood donation, based on perceived risk. Today, thanks to modern donor screening, pathogen reduction, and manufacturing safeguards, those policies have changed. While individuals with hemophilia are still generally deferred from donating blood due to the risk of bleeding from venipuncture, their sexual partners are no longer automatically excluded under current FDA guidelines. It’s a reminder that the story of plasma — like all of transfusion medicine — is one of evolving science, ethics, and trust. Final Thought: Precision Is the Point Fresh frozen plasma is broad and blunt — it works when you don’t know exactly what’s wrong, or when you need many things at once. But these plasma-derived pharmaceuticals? They’re sharp tools. Precision instruments. Each one represents decades of innovation aimed at solving specific physiologic problems. So before you grab FFP “just in case,” consider: Is there a better-targeted option? Could the patient benefit more from albumin, or a specific concentrate? Are you using plasma because it’s easy — or because it’s best? Transfusion medicine doesn’t end with a blood bag. Sometimes the most powerful plasma products don’t look like blood at all.

This is the third installment in my four-part series on plasma. In Part I, we broke down the different types of plasma products — from FFP and PF24 to thawed and cryopoor plasma. In Part II, we focused on appropriate indications: when plasma actually helps, why it works, and how to assess response. Today, we’re talking about what plasma doesn’t  do — and why so much of its use is misguided. Fresh frozen plasma often gets ordered in moments of uncertainty. A mildly elevated INR before a procedure. A confusing coagulopathy in a bleeding patient. A nagging feeling that “we should do something.” And too often, that “something” is FFP. But plasma isn’t harmless. It’s a blood component — with all the risks that come with transfusion: TRALI, TACO, allergic reactions, alloimmunization. It takes time to type, thaw, and deliver. And most importantly, it only works when there’s a factor deficiency, and even then, its effect is modest and unpredictable. Let’s start with the INR, because it’s the most common reason people reach for plasma. When the INR creeps above 1.3 — 1.4 — maybe 1.6 — it starts to feel uncomfortable, especially if a procedure is coming up. But the truth is, an INR in this range does not predict bleeding, and FFP won’t reliably correct it. In fact, most units of FFP have an INR around 1.3–1.5 themselves. That means even if you transfuse 2 or 3 units, you’re not pushing the needle much — just adding volume and risk without meaningful change. This is especially true in liver disease, where INR elevation doesn’t tell the full story. Patients with cirrhosis have decreased synthesis of both procoagulant and anticoagulant factors — including protein C, protein S, and antithrombin. The result is a rebalanced hemostatic system, one that may actually lean prothrombotic , not bleeding-prone. That’s why routine correction of INR before procedures in liver patients has fallen out of favor — particularly for paracentesis, central lines, and even some biopsies. The INR may look alarming, but it doesn’t reflect true bleeding risk in this context. Another common misuse: using FFP as a volume expander. It isn’t. FFP is high-volume (about 200–250 mL per unit), but it comes with clotting proteins, antibodies, and potential for serious reactions. If your patient needs volume, give crystalloids. If they need oncotic support, give albumin. Plasma should never be used to “fill the tank” — especially in patients at risk of TACO or other volume-sensitive complications. What To Use Instead If FFP is off the table, what is  appropriate? That depends on what you’re treating. I. Prothrombin Complex Concentrates (PCCs) First-line for urgent warfarin reversal (e.g., in bleeding or before emergent surgery). Contains factors II, VII, IX, and X — more concentrated and faster-acting than plasma. Administered in small volumes, reducing risk of volume overload. Effectively lowers INR and restores coagulation within minutes. Often used in trauma, neurosurgical bleeds, or GI hemorrhage in anticoagulated patients. II. Cryoprecipitate Contains fibrinogen, vWF, factor VIII, and factor XIII. Best option when fibrinogen is low (<100–150 mg/dL), especially in DIC, trauma, or obstetric hemorrhage. FFP contains some fibrinogen, but not enough to meaningfully raise levels in hypofibrinogenemia. Dose is typically 1 unit per 10 kg body weight. III. Platelets Appropriate for bleeding due to thrombocytopenia or qualitative platelet defects. If platelet count is <50K and the patient is bleeding or undergoing surgery, platelets are your answer — not plasma. Also critical in DIC, bone marrow failure, and massive transfusion protocols. IV. Vitamin K Often overlooked, but essential for non-urgent reversal of warfarin or correction of nutritional/coagulopathic deficiencies. Can be given orally or IV depending on urgency; IV acts faster but should be infused slowly to avoid rare anaphylactoid reactions. Especially helpful in malnourished patients, those with fat malabsorption, or prolonged NPO status. Prolonged antibiotic use — especially with broad-spectrum agents — can cause deficiency by disrupting gut flora that synthesize vitamin K₂ (menaquinone). Won’t stop bleeding immediately, but plays a critical role in restoring normal hemostasis over hours to days. V. Factor Concentrates (Targeted Use Only) Recombinant or plasma-derived factor VIII, IX, XIII, and vWF concentrates exist for hereditary deficiencies or inhibitor-related bleeding. FEIBA (Factor Eight Inhibitor Bypassing Activity) is used in patients with hemophilia A and inhibitors — it contains activated clotting factors that bypass the need for factor VIII. These are expensive, potent agents — used under specialist guidance, not general coagulopathy. Transfusion Isn’t a Substitute for a Plan Before you reach for FFP, ask yourself: Do I know what I’m treating? Is there a documented or suspected factor deficiency? Is plasma the right product, or am I just trying to do something? How will I assess response? If you don’t have clear answers, don’t transfuse. Bottom Line: FFP isn’t for mild coagulopathy. It’s not for pre-procedure reassurance. And it’s definitely not for volume. Transfusing “just in case” isn’t good medicine — it’s defensive, imprecise, and wasteful. Plasma saves lives when used well. But that requires clarity, restraint, and a commitment to treating the patient — not the INR. Next up: the pharmaceutical cousins of plasma — albumin, IVIG, and more.

This is the second post in my four-part series on plasma products — what they are, when to use them, and why they’re so often misunderstood. In Part I, we broke down the differences between FFP, PF24, thawed plasma, and cryopoor plasma. Today, we’re turning to indications: the clinical scenarios where plasma actually helps, how it works in those settings, and what to consider when deciding whether it’s the right tool for the job. Once upon a time, fresh frozen plasma (FFP) was the Swiss Army knife of coagulation management. Long before recombinant factors, PCCs, or viscoelastic testing, we had plasma — frozen within 8 hours of collection, rich in clotting factors, and theoretically capable of correcting just about anything. And so we used it for everything. For decades, FFP was infused for elevated INRs, thrombocytopenia, mild oozing, or even just a bad “feeling” in the OR. In the early days of trauma resuscitation, the concept of 1:1:1 transfusion (plasma:platelets:RBCs) emerged from military and civilian protocols aiming to mimic whole blood and prevent dilutional coagulopathy. But as tools and evidence evolved, we learned something critical: FFP only works when the problem is a true factor deficiency — and even then, it’s not always the best option. Despite these advances, FFP still gets ordered reflexively. That elevated INR? Plasma. Platelets a little low? Plasma. Bleeding? Plasma — even when the root cause has nothing to do with factor levels. Let’s move past that. Because FFP is not a vitamin. It’s a blood product with real risks, finite benefits, and a narrow set of appropriate indications. Appropriate Indications for FFP (and Related Plasma Products) I. Thrombotic Thrombocytopenic Purpura (TTP) Plasma is essential, not optional, in this rare but life-threatening condition. Why it works: TTP is caused by a deficiency or inhibition of ADAMTS13, a protease that cleaves vWF multimers. FFP replenishes functional ADAMTS13 during plasma exchange. How it’s used: FFP is the standard replacement fluid for therapeutic plasma exchange (TPE), often given daily for 5–7 days or more. Alternatives: Cryopoor plasma can be used if vWF reduction is also desired, though it's not widely available. Measuring effectiveness: Monitor LDH, platelet count, and neurologic symptoms daily — improvement signals clinical response. Pearl: This is one of the few times plasma is curative, not just supportive. II. Disseminated Intravascular Coagulation (DIC) with Active Bleeding In DIC, widespread clotting consumes platelets and factors, leading to bleeding. Why it works: FFP replaces the consumed clotting factors — especially in patients with bleeding and prolonged PT/aPTT. When to use: Only in the setting of active bleeding or an upcoming invasive procedure; don’t transfuse based on labs alone. Dosing: Usually 10–15 mL/kg, guided by clinical status and factor levels. Measuring effectiveness: Watch for stabilization of bleeding and normalization of PT/aPTT — but correction may be partial or transient. Pearl: Platelets and cryoprecipitate may also be needed. FFP alone won’t fix low fibrinogen. III. Liver Disease with Bleeding or High-Risk Procedure The cirrhotic liver synthesizes most clotting factors — when it fails, so does hemostasis. Why it works: FFP provides a broad spectrum of factors, especially when PT/INR are prolonged and bleeding is present. Caution: Elevated INR in cirrhosis doesn’t always reflect bleeding risk; thromboelastography (TEG/ROTEM) may give better insight. When to use: For active bleeding or before high-risk interventions (e.g., liver biopsy, large paracentesis), if there's demonstrable coagulopathy. Measuring effectiveness: Clinical bleeding control matters more than INR correction; labs often lag behind or mislead. Pearl: Overtransfusion may worsen portal hypertension and increase the risk of TACO. Use intentionally. IV. Massive Transfusion Protocols (MTPs) Hemorrhagic shock can rapidly dilute clotting factors, even without baseline coagulopathy. Why it works: Plasma helps restore clotting capacity during large-volume resuscitation (typically >1 blood volume within 24h). When to use: In trauma, obstetric hemorrhage, or surgical bleeding with major blood loss. Typical ratios: 1:1:1 of plasma, platelets, and RBCs is often used, though this may vary based on institution and patient response. Measuring effectiveness: Clinical stabilization, viscoelastic testing (if available), fibrinogen >150–200 mg/dL, PT/aPTT trends. Pearl: MTP is about anticipation, not reaction. Plasma should be ready before the patient becomes coagulopathic. V. Rare Factor Deficiencies (When Specific Factor Concentrates Aren’t Available) FFP is still a fallback in rare cases. Examples: Factor V and other factors that lack commercial concentrates. Why it works: FFP provides small amounts of each factor, enough to bridge mild to moderate bleeding risk. When to use: During bleeding episodes or peri-procedurally in known deficiency patients. Dosing and response: Requires large volumes to achieve even modest factor increases; monitor with specific assays if available. Pearl: Always check whether recombinant or plasma-derived factor concentrates exist first — they’re safer and more effective. VI. Cryopoor Plasma (Niche Use) Rarely needed — but notable. What it is: The plasma that remains after cryoprecipitate is removed from FFP. Why it’s used: Occasionally used in refractory cases of TTP. Availability: May be restricted to certain centers; not a routine product. Pearl: Know that it exists — and when to call the blood bank about it. One More Thing: FFP Changes Over Time Once thawed, both FFP and plasma frozen within 24 hours (PF24) are stored at 1–6°C and relabeled thawed plasma after 24 hours. They’re typically good for 5 days, but labile factors like V and VIII degrade with time. That means thawed plasma may not be appropriate when you need high levels of those factors — such as in TTP or factor V deficiency — but it’s usually adequate for liver disease or DIC. Final Thought: Know What You’re Treating Before ordering FFP, ask: Is there a documented or strongly suspected factor deficiency? Is the patient bleeding or about to bleed? Will plasma meaningfully change the outcome? Do you have a way to measure effectiveness? Transfusing FFP without an indication is like prescribing antibiotics for a viral sore throat — satisfying in the moment, but clinically empty. And it isn’t harmless. FFP is powerful. But only when used with precision. Coming up next: When not  to order FFP — and what to use instead.